The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
admin
ساينس ديلي - الكل
24 July, 2026
Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety risks.
